Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275.1 USD | +1.73% | +0.82% | +25.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.25 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an enterprise value anticipated at 3.66 times the sales for the current fiscal year, the company turns out to be overvalued.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.12% | 12.21B | B+ | ||
+43.36% | 54.63B | B- | ||
-5.31% | 39.92B | B | ||
+37.52% | 38.82B | A | ||
+14.75% | 26.86B | B- | ||
-12.56% | 26.22B | C | ||
-22.45% | 18.78B | B | ||
+0.04% | 12.16B | B+ | ||
+26.04% | 11.94B | C+ | ||
-11.83% | 10.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UTHR Stock
- Ratings United Therapeutics Corporation